Page 103 - Sohini Das

Sun Pharma posts Rs 1,433-crore pre-tax profit in Q2, meets estimates

Sales or income from operations was Rs 7,949 crore, up 16 per cent year-on-year

Sun Pharma ties up with AstraZeneca to sell novel oncology drugs in China

Sun Pharma has been working out deals through this year to gain foothold in the Chinese market

Cipla's Q2 profit before tax grows 34% on Indian business revival

Co undertook a distribution network restructuring exercise in the last few months

Lupin no longer bullish on Japanese market as price rules prove a dampener

Volumes in that market keep growing at 10 per cent a year, but from a value perspective, the growth is single-digit at best, the firm says

Multiplexes' revenue from convenience fee rises as online ticket sales grow

Data analysed by SBICap Securities show revenue from convenience fees has grown at a compound annual rate of 85 per cent for multiplex chain operator Inox Leisure and 58 per cent for PVR

Sales of anti-malarial drugs jump 76% on the back of long rainy season

The long, rainy season and the ensuing rise in antibiotic (anti-infective category) sales boosted the overall growth of the domestic pharma industry during the September quarter

EcoSport to PhonePe, children play a key role in moving the needle in ads

Children are no longer awareness builders; recent ads have portrayed them as key influencers in family purchases

Seven of top 10 drug brands sold in India are from multinational companies

The top 10 corporates contribute to 43% of the domestic pharma market

Slowdown in real estate sector hampering screen additions for multiplexes

Multiplexes are now either expanding within existing properties or converting single screens into multiple screens through partnerships

Indian pharmaceutical companies spread business to avoid regulatory ire

Increased USFDA import alerts could be reason for finding alternative sites

Cipla looks at digital media for expanding footprint and reach customers

The pharma major looks to expand its footprint by driving up the diagnosis around diseases, uses digital media to take the brand directly to the end-user

Digital to be 50% of our India business, says Ketchum Global CEO

The global chief executive officer (CEO) also indicated there were no plans to merge the Omnicom Group's PR networks in India unlike what it did in Singapore and some European countries

Bills for pills: Antibiotics could be govt's next segment for price cap

Centre likely to consider rationalising trade margins

India's leading drugmakers stocking up to avoid supply disruptions

Have increased raw material buffer stock by at least 40 days in recent months

Maharashtra govt plans to deliver emergency medicines through drones

Zipline drones will make on-demand and emergency deliveries of blood products, vaccines and life-saving medications

Pharma PSUs likely to sign MoU with LMA for sale of surplus land

The PSUs thus are hopeful that the sale process could now be expedited

Anti-tuberculosis drug market continues to shrink for private firms

Lupin, the largest player in India's anti-TB market, too admitted that in anti-TB segment, the focus on branded business has declined in the past few years

Airtel Africa's mobile money, data growth to double by 2024: Experts

The operator continues to invest in the 4G network, having added nearly 1,500 sites

Lupin divests its Japanese injectables business to Abu Dhabi company

Company is looking at enhancing efficiencies in Japanese market which is facing pricing pressure

Airtel Africa data and mobile money penetration to double in next 5 years

Airtel is preparing for the launch of the Mobile Money business in Nigeria